Enzyme – Page 3

AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment

6 months ago talkbio0Tagged Approved, AstraZeneca, Epidermal Growth Factor Receptor, EU, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Tagrisso

AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment

FDA Rejects Subcutaneous Version of J&J’s Lung Cancer Drug Rybrevant Due to Manufacturing Concerns

6 months ago talkbio0Tagged Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, manufacturing issues, Mutation, Non-Small Cell Lung Carcinoma, Rejection, Subcutaneous Rybrevant, United States Food and Drug Administration

FDA rejection, J&J, Subcutaneous Rybrevant, Manufacturing issues, Lung cancer drug, Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutations

Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

6 months ago talkbio0Tagged disease treatment, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, HSCT-TMA, Improvement, Infrequent, Inhibitor, Lectin, MASP2 protein, human, narsoplimab, Overall Survival, Psychological inhibition

Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

6 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy

Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile

6 months ago talkbio0Tagged Biclonics, Cancer of Neck, Clinical Trials, Congress (U.S. Legislature), Epidermal Growth Factor Receptor, ESMO, LGR5 gene, Merus, Petosemtamab

Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5

Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement

7 months ago talkbio0Tagged Alteogen, Cancer Therapeutic Procedure, Daiichi, Enhertu, Homo sapiens, hyaluronidase, Sankyo, subcutaneous

Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment

Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa

8 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, concerns, Effectiveness, FGFR3 protein, human, Inhibitor, J&J, Malignant neoplasm of urinary bladder, Safety, Tyra Biosciences, TYRA-300

Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

8 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration